These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1924666)

  • 21. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 22. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 25. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
    Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
    Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluphenazine activity and antipsychotic response.
    Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
    Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
    Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Hubbard JW; Midha KK
    Ther Drug Monit; 1990 May; 12(3):268-76. PubMed ID: 2349611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
    Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
    Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
    Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Blood serum concentration of long-acting fluphenazine in patients with various forms of schizophrenia].
    Pempkowiak L; Januszkiewicz-Grabiasowa A; Góra S
    Psychiatr Pol; 1979; 13(1):1-8. PubMed ID: 419224
    [No Abstract]   [Full Text] [Related]  

  • 35. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
    Midha KK; Hubbard JW; Marder SR; Hawes EM; Van Putten T; McKay G; May PR
    Psychopharmacology (Berl); 1987; 93(3):369-73. PubMed ID: 3124166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluphenazine pharmacokinetics and therapeutic response.
    Dysken MW; Javaid JI; Chang SS; Schaffer C; Shahid A; Davis JM
    Psychopharmacology (Berl); 1981; 73(3):205-10. PubMed ID: 6787637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
    Norman TR; Marriott PF; Kimber NM; Burrows GD
    Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
    Dencker SJ; Johansson R; Lundin L; Malm U
    Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.